← 產業報告目錄
Bevacizumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Abevmy, Alymsys, Avastin, Avzivi, Avzivi tnjn, Aybintio, Bambevi, Equidacent, Jobevne, Lextemy, Lytenava, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev, and others (including products approved in developing countries and pipeline products), By Application, By Distribution Channel, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-25頁數 170報告編號 INSIGHTACE-17c33ba216
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Bevacizumab Biosimilar Market is poised to register a CAGR of 9.0%.
At its core, Bevacizumab Biosimilar pertains to a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor a (vegf-a) biologic activity (an essential endothelial cell mitogen and survival factor). Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
Market momentum is driven by mounting need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Bevacizumab Biosimilar Market Snapshot
Chapter 4. Global Bevacizumab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Porter's Five Forces Analysis
4.6. Impact of COVID 19 Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Major Investment, Partnerships and Collaborations in Biosimilar Industry
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Products:
5.2.1. Avastin
5.2.2. Mvasi
5.2.3. Zirabev
5.2.4. Aybintio
5.2.5. Other Clinical Trial Products
Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Applications & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Applications:
6.2.1. Colorectal cancer
6.2.2. Non-small cell lung cancer
6.2.3. Glioblastoma
6.2.4. Renal cell carcinoma
6.2.5. Cervical cancer
6.2.6. Ovarian cancer
Chapter 7. Market Segmentation 3: By End-Users Estimates & Trend Analysis
7.1. By End-Users & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By End-Users:
7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels
Chapter 8. Bevacizumab Biosimilar Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Products, 2025-2034
8.1.2. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Applications, 2025-2034
8.1.3. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by End-Users, 2025-2034
8.1.4. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2025-2034
8.2. Europe
8.2.1. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, 2025-2034
8.2.2. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, 2025-2034
8.2.3. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, 2025-2034
8.2.4. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Country, 2025-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, 2025-2034
8.3.2. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, 2025-2034
8.3.3. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, 2025-2034
8.3.4. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Country, 2025-2034
8.4. Latin America
8.4.1. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, (US$ Million) 2025-2034
8.4.2. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, (US$ Million) 2025-2034
8.4.3. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, (US$ Million) 2025-2034
8.4.4. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by country, (US$ Million) 2025-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, (US$ Million) 2025-2034
8.5.2. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, (US$ Million) 2025-2034
8.5.3. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, (US$ Million) 2025-2034
8.5.4. Middle East & Africa Bevacizumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2025-2034
Chapter 9. Competitive Landscape
9.1. Company Profiles
9.1.1. Amgen Inc.
9.1.2. Amneal Pharmaceuticals, Inc.
9.1.3. Betta Pharmaceuticals/Beijing Mabworks
9.1.4. Biocon
9.1.5. Biosimilar Collaborations Ireland Limited
9.1.6. Bio-Thera Solutions, Ltd.
9.1.7. Celltrion, Inc.
9.1.8. Cipla
9.1.9. Dr. Reddy's Laboratories
9.1.10. FGK Representative Service GmbH
9.1.11. Hetero
9.1.12. Innovent Biologics
9.1.13. mAbxience Holding, S.L.
9.1.14. Outlook Therapeutics Limited
9.1.15. Pfizer Inc.
9.1.16. Reliance Life Sciences
9.1.17. Roche Registration GmbH
9.1.18. Samsung Bioepis NL B.V.
9.1.19. Sandoz Inc.
9.1.20. Shanghai Henlius Biotech
9.1.21. STADA Arzneimittel AG
9.1.22. TOT BIOPHARM
9.1.23. Zydus Cadila
9.1.24. AstraZeneca PLC
9.1.25. Samsung Bioepis Co., Ltd.
9.1.26. Organon & Co.
9.1.27. Prestige Biopharma Ltd.
9.1.28. Zhejiang Teruisi Pharmaceutical Co., Ltd.
9.1.29. Apotex Inc.
9.1.30. Tanvex BioPharma Inc.
9.1.31. Other Prominent Player
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們